Why the study?
The study was conducted to evaluate the real-world effect of dimethyl fumarate on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis and compare these findings with clinical trial results.
Does dimethyl fumarate reduce brain atrophy and new lesions in a real-world cohort of patients with relapsing-remitting multiple sclerosis?
Does dimethyl fumarate reduce brain atrophy and new lesions in a real-world cohort of patients with relapsing-remitting multiple sclerosis?
Real-world MRI data confirms that dimethyl fumarate effectively limits brain atrophy and new lesion formation in RRMS patients, consistent with phase III clinical trials.
OBJECTIVE: Evaluate the real-world effect of dimethyl fumarate (DMF) on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis (RRMS) and compare with results from clinical trials. METHODS: Magnetic resonance imaging (MRI) data from 102 RRMS patients were retrospectively collected and processed using icobrain to assess brain atrophy and to assist semi-manual lesion count. RESULTS: Mean (±SD) annualized percent brain volume change in the first 3 years after DMF-initiation were: -0.33 ± 0.68, -0.10 ± 0.60, and - 0.35 ± 0.71%/year, respectively. No new FLAIR lesions were detected in 73.7%, 77.3%, and 73.3% of the patients during years 1, 2, and 3. CONCLUSIONS: Results of this real-world study were consistent with previous DMF phase III clinical trials, supporting the generalizability of the effects observed in clinical trials to the real-world clinical setting.
No takes yet. Share an insight, caveat, or question.
Krieger et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: